Mechanisms of angiotensin II-dependent progression to heart failure

Novartis Foundation Symposium

Volumn 274, Issue , 2006, Pages 58-68

  Nemer, Mona ^b   Dali Youcef, Nassim ^b   Wang, Hao ^a   Aries, Anne ^a   Paradis, Pierre ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; PROTEIN BCL 2;

ANIMAL; APOPTOSIS; ARTICLE; CONGESTIVE HEART FAILURE; HEART DISEASE; HEART MUSCLE; METABOLISM; MITOCHONDRION; MOUSE; MUSCLE CELL; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; TRANSGENE; TRANSGENIC MOUSE; UPREGULATION;

ANGIOTENSIN II; ANIMALS; APOPTOSIS; HEART DISEASES; HEART FAILURE, CONGESTIVE; MICE; MICE, TRANSGENIC; MITOCHONDRIA; MUSCLE CELLS; MYOCARDIUM; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSGENES; UP-REGULATION;

EID: 34347239076     PISSN: 15282511     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (18)

1. Adams JM 2003 Ways of dying: multiple pathways to apoptosis. Genes Dev 17:2481-2495
2. Aries A, Paradis P, Lefebvre C, Schwartz RJ, Nemer M 2004 Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci USA 101:6975-6980
3. Baker KM, Booz GW, Dostal DE 1992 Cardiac actions of angiotensin II: Role of an intracardiac renin- angiotensin system. [Review] Annu Rev Physiol 54:227-241
4. Braunwald E, Domanski MJ, Fowler SE et al 2004 Angiotensin-converting- enzyme inhibition in stable coronary artery disease. N Engl J Med 351:2058-2068
5. Crow MT, Mani K, Nam YJ, Kitsis RN 2004 The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res 95:957-970
6. Dahlof B, Devereux RB, Kjeldsen SE et al 2002 Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995-1003
7. Dostal DE, Baker KM 1999 The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 85:643-650
8. Gullestad L, Aukrust P 2005 Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 95:17C-23
9. Harada M, Itoh H, Nakagawa O et al 1997 Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation 96:3737-3744
10. Ito M, Oliverio MI, Mannon PJ et al 1995 Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 92:3521-3525
11. Kelly DP, Scarpulla RC 2004 Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev 18:357-368
12. Kim NN, Villarreal FJ, Printz MP, Lee AA, Dillmann WH 1995 Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts. Am J Physiol 269: E426-437
13. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M 2000 Overexpression of angiotensin II type 1 receptor in cardiomyocytes induces cardiac hypertrophy and remodelling. Proc Natl Acad Sci USA 97:931-936
14. Phillips MI, Kagiyama S 2002 Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs 3:569-577
15. Sil P, Sen S 1997 Angiotensin II and myocyte growth: role of fibroblasts. Hypertension 30:209-216
16. Wallace DC 2000 Mitochondrial defects in cardiomyopathy and neuromuscular disease. Am Heart J 139:S70-85
17. Wang J, Paradis P, Lefebvre C, Nemer M 2005 Convergence of protein kinase C and JAK-STAT signaling on transcription factor GATA-4. Mol Cell Biol 25:9829-9844
18. Wu Z, Puigserver P, Andersson U et al 1999 Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98:115-124